tbuckley/cabot-search huggingface dataset:
STATE OF THE BLOOD IN ERYSIPELAS.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
(17) Spasticity and vascular lesions
Authors: B.R. Allen
Journal: British Journal of Dermatology (1978)

Journal Article (17) Spasticity and vascular lesions Get access B.R. Allen B.R. Allen General Hospital, Nottingham Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 99, Issue s16, 1 December 1978, Pages 42–43, https://doi.org/10.1111/j.1365-2133.1978.tb15239.x Published: 01 December 1978
Allied Health Education And Accreditation
Authors: William R. Burrows
Journal: JAMA (1988)

<h3>SHARED RESPONSIBILITY AND MUTUAL SUPPORT: THE AMA AND ALLIED HEALTH EDUCATION AND ACCREDITATION</h3> For more than 50 years the American Medical Association (AMA) and its members have recognized the value of actively participating in and promoting quality education for allied health personnel in order to maintain an adequate supply of qualified professionals whose functions include complementing, facilitating, or assisting in the work of physicians and other specialists in the health care system. <h3>Physician Contributions to the Accreditation Review Process</h3> Physician contributions to the accreditation review process, the principal activity through which the AMA promotes quality in education for allied health professionals, have been especially significant in various types of activities now coordinated by the AMA Committee on Allied Health Education and Accreditation (CAHEA). As teachers and medical directors in allied health educational programs, as members of review committees, and as site visitors, physicians make significant contributions to professional standards, to
24TH CONGRESS ON OCCUPATIONAL HEALTH
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Metabolism and enterohepatic circulation of a new conjugated bile acid analogue: Ursodeoxycholyl-n-benzyltaurine Dept. of Medicine, U. California, San Diego, CA and *Medical College of Virginia, Richmond, VA
Journal: Hepatology (1995)

Irinotecan-containing regimens are known to be active and tolerable in patients with non-small cell lung cancer (NSCLC). A randomized phase II trial was conducted to evaluate the efficacy of irinotecan plus paclitaxel or gemcitabine for previously untreated stage IIIB or stage IV NSCLC.Previously untreated patients with adequate organ function who gave written informed consent were randomly assigned to receive irinotecan (50 mg/m2 on days 1, 8, and 15) plus paclitaxel (180 mg/m2 on day 1) every 4 weeks (IP group) or irinotecan (100 mg/m2 on days 1 and 8) plus gemcitabine (1000 mg/m2 on days 1 and 8) every 3 weeks (IG group). The primary endpoint was the response rate. We also evaluated the relationship of response and toxicity to polymorphisms of the uridine diphosphate glucuronosyltransferase (UGT) gene.Eighty patients were enrolled, and 78 patients were eligible (38 in the IP group and 40 in the IG group). The response rate was 31.6% (95% confidence interval: 17.5–48.7%) in the IP group and 20.0% (9.1–35.6%) in the IG group. The median progression-free survival time was 86 days and 145 days, respectively. Both regimens were well tolerated. The most common severe adverse event was grade 4 neutropenia (36.8% and 10.0%, respectively), which was associated with UGT1A1*6 and UGT1A1*27. UGT polymorphisms did not correlate with response.Irinotecan plus paclitaxel may be more active against NSCLC than irinotecan plus gemcitabine. The UGT1A1*6 and UGT1A1*27 genotypes might be useful predictors of grade 4 neutropenia in patients who receive irinotecan-based chemotherapy.
Inspiratory muscle weakness in chronic heart failure: role of nutrition and electrolyte status and systemic myopathy.
Authors: C McParland, E F Resch, B Krishnan, Y Wang, B Cujec, C G Gallagher
Journal: American Journal of Respiratory and Critical Care Medicine (1995)

Inspiratory muscle weakness has been demonstrated in ambulatory, stable chronic heart failure (CHF) and may contribute to dyspnea during daily living. However, the mechanisms underlying this weakness are unknown. Malnutrition and electrolyte depletion are recognized complications of CHF that may impair skeletal muscle function, and limb muscle weakness and myopathic changes have also been demonstrated in CHF. We examined whether nutrition and electrolyte status contribute to the reduced skeletal muscle strength and whether inspiratory muscle weakness in CHF is part of general skeletal muscle weakness. We measured maximum inspiratory and expiratory mouth pressures as indices of respiratory muscle strength, maximum hand-grip strength as an index of limb muscle strength, anthropometric indices, serum albumin, and total lymphocyte count as indices of nutritional status, and serum electrolytes in 15 stable patients with chronic cardiac pump failure who had no evidence of primary lung disease, and in 15 age-and-sex-matched healthy controls. As compared with the matched controls, the CHF patients had reduced inspiratory muscle strength (p < 0.0025), but their expiratory and limb muscle strength were not significantly reduced. CHF patients were not malnourished; they were heavier than matched controls because of increased body fat (p < 0.05). Serum sodium was significantly lower in the CHF patients than in the controls (p < 0.01), but was within the normal range in both groups.(ABSTRACT TRUNCATED AT 250 WORDS)
Radium Poisoning: 40 Years Later
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Update: Adverse Events Associated With Anthrax Prophylaxis Among Postal Employees—New Jersey, New York City, and the District of Columbia Metropolitan Area, 2001
Journal: JAMA (2001)

Antimicrobial prophylaxis to prevent inhalational anthrax has been recommended for persons potentially exposed to Bacillus anthracis as a result of the recent bioterrorist attacks. During October 26-November 6, 2001, an epidemiologic evaluation to detect adverse events associated with antimicrobial prophylaxis was conducted among 8,424 postal employees who had been offered antimicrobial prophylaxis for 60 days in New Jersey (NJ), New York City (NYC), and one postal facility in the District of Columbia (DC). This report summarizes preliminary results of that evaluation, which found that few employees receiving antimicrobial prophylaxis sought medical attention for symptoms that may have been associated with anaphylaxis. Persons with exposures to B. anthracis related to the bioterrorist attacks should complete the full 60-day course of antimicrobial prophylaxis.
Minerva
Authors: Neil McGowan, James Walker
Journal: BMJ (2007)

Terminal sterilization is considered the preferred means for the production of sterile drug products because it affords enhanced safety for the patient as the formulation is filled into its final container, sealed, and sterilized. Despite the obvious patient benefits, the use of terminal sterilization is artificially constrained by unreasonable expectations for the minimum time-temperature process to be used. The core misunderstanding with terminal sterilization is a fixation that destruction of a high population of a resistant biological indicator is required. The origin of this misconception is unclear, but it has resulted in sterilization conditions that are extremely harsh (15 min at 121 °C, of F<sub>0</sub> &gt; 8 min), which limit the use of terminal sterilization to extremely heat-stable formulations. These articles outline the artificial nature of the process constraints and describe a scientifically sound means to expand the use of terminal sterilization by identifying the correct process goal—destruction of the bioburden present in the container prior to sterilization. Recognition that the true intention is bioburden destruction in routine products allows for the use of reduced conditions (lower temperatures, shorter process dwell, or both) without added patient risk. By focusing attention on the correct process target, lower time-temperature conditions can be used to expand the use of terminal sterilization to products unable to withstand the harsh conditions that have been mistakenly applied. The first article provides the background and describes the benefits to patient, producer, and regulator. The second article includes validation and operational advice that can be used in the implementation. <i>LAY ABSTRACT:</i> Terminal sterilization is considered the preferred means for the production of sterile drug products because it affords enhanced safety for the patient as the formulation is filled into its final container, sealed, and sterilized. Despite the obvious patient benefits, the use of terminal sterilization is artificially constrained by unreasonable expectations for the minimum time-temperature process to be used. These articles outline the artificial nature of the process constraints and describe a scientifically sound means to expand the use of terminal sterilization by identifying the correct process goal—destruction of the bioburden present in the container prior to sterilization. By focusing attention on the correct process target, lower time-temperature conditions can be used to expand the use of terminal sterilization to products unable to withstand the harsh conditions that have been mistakenly applied. The first article provides the background, and describes the benefits to patient, producer, and regulator. The second article includes validation and operational advice that can be used in the implementation.
Baseline neutrophil-lymphocyte ratio as a prognostic factor for patients with resectable gastric cancer undergoing adjuvant chemotherapy
Authors: M.M. Laterza, A. Petrillo, J. Ventriglia, A. Fabozzi, B. Savastano, A. Diana, E. Martinelli, F. Morgillo, F. Ciardiello, F. De Vita
Journal: Annals of Oncology (2015)
How Useful Are Cytomegalovirus Cultures in Patients with HIV Infection?
Authors: John J. Zurlo
Journal: Annals of Internal Medicine (1993)

Letters1 August 1993How Useful Are Cytomegalovirus Cultures in Patients with HIV Infection?John J. Zurlo, MD, Michael A. Polis, MD, and Henry Masur, MDJohn J. Zurlo, MDSearch for more papers by this author, Michael A. Polis, MDSearch for more papers by this author, and Henry Masur, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-119-3-199308010-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We are grateful that the article by Salmon and colleagues [1] about the predictive value of CMV viremia in patients with HIV infection was brought to our attention. Their data are similar to ours and support rather than refute our arguments. Their patients were considered to have CMV viremia or not based on one or more cultures done during the 3 months before and after the diagnosis of AIDS. Our study tested the first blood and urine cultures taken as part of routine screening of prospective patients seen for investigational protocols [2]. Initial and subsequent evaluations for end-organ ...References1. Salmon D, Lacassin F, Harzic M, Leport C, Perronne C, Bricaire F, et al. Predictive value of cytomegalovirus viraemia for the occurrence of CMV organ involvement in AIDS. J Med Virol. 1990; 32: 160-3. Google Scholar2. Zurlo JJ, O'Neill D, Polis MA, Manischewitz J, Yarchoan R, Baselar M, et al. Lack of clinical utility of cytomegalovirus blood and urine cultures in patients with HIV infection. Ann Intern Med. 1993; 118: 12-7. Google Scholar3. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE, and the Zidovudine Epidemiology Study Group. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis. 1992; 166:1223-7. Google Scholar4. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr. 1991; 4:770-6. Google Scholar5. Pertel P, Hirschtick R, Phair J, Chmiel J, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr. 1992; 5:1069-74. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1993Volume 119, Issue 3Page: 247-249KeywordsAIDSCytomegalovirus infectionDrug therapyHIV infectionsLymphocytesPathogensProphylaxisSystemic diseasesUrineViremia ePublished: 15 August 2000 Issue Published: 1 August 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
LETTER FROM PARIS.
Authors: None A. B.
Journal: JAMA (1889)

(FROM OUR OWN CORRESPONDENT.) <h3>THE PARIS SCHOOL OF MEDICINE—I.</h3> I propose describing as briefly as possible the Paris School of Medicine and the subjects that are taught in it. Those who have not visited this city for the last 15 or 20 years, will scarcely recognize the quarter in which the building of the School of Medicine stands, as the place has become completely transformed. The old building has been considerably enlarged, and fitted up with laboratories for carrying on various researches. The old Hospital des Cliniques which stood opposite has been razed to the ground and the Ecole Pratique has been built on its site. It contains eight pavilions for students carrying on dissection. Each pavilion consists of sixteen tables, and each table supplies room and furnishes material gratuitously to five students. The degree of Doctor of Medicine in the University of France is conferred by the Faculties of
Abstract 1352: Serum neurofilament light (NfL), glial fibrillary acidic protein (GFAp) and tau protein are possible serum biomarkers for activity of brain metastases and gliomas
Authors: Jason Porter, Adriana Hepner, Manjari Pandey, Philippe Prouet, Felicia Hare, Syed S. Nasir, Madison Boles, Henrik Zetterberg, Kaj Blennow, Michael Martin
Journal: Cancer Research (2019)

Abstract Introduction: While the morbidity and mortality attributable to gliomas and brain metastases is significant, there are currently no approved biomarkers for detecting and monitoring intracranial disease and imaging remains the primary modality. Blood levels of the neurofilament light (NfL) and tau, as well as glial fibrillary acidic protein (GFAp) show promise as biomarkers for brain injury. We therefore hypothesized that these biomarkers would correlate with CNS activity of gliomas and brain metastases. Methods: Serum concentrtaions of NfL, tau and GFAp were measured using the ultrasensitive single molecule array (Simoa) technology (Quanterix, Lexington, MA). Levels of the three proteins were then correlated with status of gliomas and brain metastases in the patients. Statistical analysis was performed using GraphPad Prism7 and all p-values were 2-tailed with an accepted 2-sided alpha level of 0.05 as statistically significant. Results: 36 patients were enrolled with varying malignancies. Both serum NfL and GFAp levels were significantly associated with the state of intracranial disease (ANOVA psNfL= 0.0307; ANOVA pGFAp=0.0348). In contrast, serum tau levels were discordant with brain involvement with cancer (ANOVA pTau= 0.1453). Conclusion: Serum NfL and GFAp both apparently vary closely with presence and activity of gliomas and brain metastases. Our studies are among the first to identify possible candidate serum biomarkers for screening and monitoring cancer patients for CNS involvement with malignancy. Further studies in larger populations are needed to expand these findings. Citation Format: Jason Porter, Adriana Hepner, Manjari Pandey, Philippe Prouet, Felicia Hare, Syed S. Nasir, Madison Boles, Henrik Zetterberg, Kaj Blennow, Michael Martin. Serum neurofilament light (NfL), glial fibrillary acidic protein (GFAp) and tau protein are possible serum biomarkers for activity of brain metastases and gliomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1352.
Surgical Risk in Cirrhosis of the Liver
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LONDON LETTER.
Authors: None G. O. M.
Journal: JAMA (1884)

London, November, 1884. Mr. Elliott, vice-chairman of the Islington Board of Guardians, at a meeting of that body stated that on making inquiries the other day he found that at the Western Hospital of the Metropolitan Asylums' Board there was only one patient under treatment, whilst the officers' salaries, uniforms, etc., of that single hospital were costing the rate-payers £4,000 a year. Since then two other fever patients had been admitted, so that the hospital was now being kept open for three patients, at the cost of about £80 a week. Several members remarked upon the great extravagance of the Asylums' Board and waste of the rate-payers' money, in keeping the hospital open at such an enormous cost for two or three patients. Dr. S. Rabbeth, senior Medical Officer of the Royal Free Hospital, in Gray's-inn road, died in that institution on Monday night, in consequence of a too-zealous devotion
General Ophthalmology
Authors: Albert M. Potts
Journal: JAMA (1965)

<h3>Parsons' Diseases of the Eye.</h3> By Sir Stewart Duke-Elder. 14th ed. 600 pp, 471 illus. $16.50. Little, Brown &amp; Co., 34 Beacon St, Boston 02106, 1964 The chief problem facing the author of any elementary textbook is what to leave out, and this in turn is determined by the author's view of the purpose of his text. The authors of<i>General Ophthalmology</i>have decided, as in previous editions, to present in semi-outline form the maximum number of disease descriptions in words and pictures that their format allows and to minimize physiopathological explanation. To assist their presentation they have redrawn many line illustrations originating elsewhere to make them as clear as possible when reproduced by the lithographic technique. Some of the photographic illustrations do not fare so well, but the copiousness of illustrative material is highly commendable. Equally commendable are the extensive reading lists after each chapter and some of the